The Biosimilars Market is expected to grow from USD 11.47 billion in 2019 to USD 98.27 billion by 2026 at a CAGR of 35.9% from 2020 to 2026.
The biosimilars market is composed to experience rewarding development over the estimated period. As per a recent article, biosimilars are projected to play a significant role in attracting the public health issue by addressing the customer needs. The growing frequency of chronic diseases across the world, especially in developing regions due to an increase in sedentary lifestyle and increasing habit of fast food consumption will result in a rising number of people suffering from such diseases. Later, the prevalence rate in advanced as well as in certain areas in developing countries will augment the demand and adoption rate of biosimilar drugs, fueling the business growth. Innovations in monoclonal antibodies are anticipated in the biosimilars market landscape in the near future. Healthcare companies are increasing their efficiency in hybridoma-based technology to develop upgraded mAbs with the support of genetic engineering. The global market is segregated on the basis of Applications as Oncology, Chronic and autoimmune disorders, Growth hormonal deficiency, Blood disorders, and Others. Based on Product Class the global market is segmented in Immunomodulators, Anti-inflammatory Agents, Others, Recombinant Hormones, and Monoclonal Antibodies.
The global Biosimilars market report provides geographical analysis covering regions, such as Europe, North America, Asia Pacific, and the Rest of The World. The market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Samsung Bioepis Co. Ltd, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, LG Life Sciences, Pfizer Inc, Eli Lilly and Company, Celltrion Healthcare, Mylan NV, Novartis AG, and others are among the major players in the global market. The companies studied in terms of product strategy and various n several growths and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.
The global Biosimilars market has been segmented as below:
By Applications
By Product Class
By Region
By Company
The report covers the below scope:
The years considered for the study are as follows:
Report Scope:
The global market report scope includes a detailed study covering underlying factors influencing the industry trends. The report covers the analysis of regional and country-level market dynamics. The scope also covers a competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes a detailed competitive outlook covering market shares and profiles key participants in the global market share. Major industry players with significant revenue share include Samsung Bioepis Co. Ltd, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, LG Life Sciences, Pfizer Inc, Eli Lilly and Company, Celltrion Healthcare, Mylan NV, Novartis AG, and others.
Why Buy this Report:
Target Audience:
The report targeted the existing players in the industry is as follows:
Free and Paid Customization based on the requirement
Report Content
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter's Five Force Analysis
5.1 Introduction
5.2 Oncology
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Chronic and autoimmune disorders
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Growth hormonal deficiency
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Blood disorders
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 Others
5.6.1 Market Overview
5.6.2 Market Size and Forecast
6.1 Introduction
6.2 Immunomodulators
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Anti-inflammatory Agents
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Others
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Recombinant Hormones
6.5.1 Market Overview
6.5.2 Market Size and Forecast
6.6 Monoclonal Antibodies
6.6.1 Market Overview
6.6.2 Market Size and Forecast
7.1 Introduction
7.2 Europe
7.2.1 Europe Market, By Applications
7.2.2 Europe Market, By Product Class
7.3 North America
7.3.1 North America Market, By Applications
7.3.2 North America Market, By Product Class
7.4 Asia Pacific
7.4.1 Asia Pacific Market, By Applications
7.4.2 Asia Pacific Market, By Product Class
7.5 Rest of The World
7.5.1 Rest of The World Market, By Applications
7.5.2 Rest of The World Market, By Product Class
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9.1 Samsung Bioepis Co. Ltd
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Stada Arzneimittel AG
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Teva Pharmaceutical Industries Ltd
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Intas Pharmaceuticals Ltd
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 LG Life Sciences
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Pfizer Inc
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 Eli Lilly and Company
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
9.8 Celltrion Healthcare
9.8.1 Company Overview
9.8.2 Product/Service Landscape
9.8.3 Financial Overview
9.8.4 Recent Developments
9.9 Mylan NV
9.9.1 Company Overview
9.9.2 Product/Service Landscape
9.9.3 Financial Overview
9.9.4 Recent Developments
9.10 Novartis AG
9.10.1 Company Overview
9.10.2 Product/Service Landscape
9.10.3 Financial Overview
9.10.4 Recent Developments
The global Biosimilars market has been segmented as below:
By Applications
By Product Class
By Region
By Company